Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma

An announcement from Citius Oncology ( (CTOR) ) is now available.

On December 1, 2025, Citius Oncology announced the commercial launch of LYMPHIR, a novel IL-2 receptor-directed fusion protein approved by the FDA for treating adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma. This launch marks a significant milestone for the company, enhancing its industry positioning by providing a new treatment option in a competitive landscape and potentially improving patient outcomes.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Spark’s Take on CTOR Stock

According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.

Citius Oncology’s stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.

To see Spark’s full report on CTOR stock, click here.

More about Citius Oncology

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. As a majority-owned subsidiary of Citius Pharmaceuticals, it operates as a stand-alone public company since August 2024, with its first commercial product, LYMPHIR, targeting a $400M+ estimated addressable U.S. market.

Average Trading Volume: 241,147

Technical Sentiment Signal: Strong Sell

Current Market Cap: $114.4M

For a thorough assessment of CTOR stock, go to TipRanks’ Stock Analysis page.